| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erika Hubina, Agnes Tóth, Gábor László Kovács, Judit Dénes, László Kovács, Miklós Gót. [Growth hormone receptor antagonist in the treatment of acromegaly]. Orvosi hetilap. vol 152. issue 18. 2011-05-27. PMID:21498159. |
on the other hand, despite the use of all current modes of treatment (surgery, radiotherapy, dopamine agonists, somatostatin analogs), a significant cohort of patients with acromegaly remains inadequately controlled. |
2011-05-27 |
2023-08-12 |
human |
| Orsolya Nemes, Emese Mezos. [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review]. Orvosi hetilap. vol 152. issue 18. 2011-05-27. PMID:21498160. |
[role of somatostatin receptor ligands in the treatment of acromegaly--literature review]. |
2011-05-27 |
2023-08-12 |
Not clear |
| Orsolya Nemes, Emese Mezos. [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review]. Orvosi hetilap. vol 152. issue 18. 2011-05-27. PMID:21498160. |
the cornerstones of medical therapy in acromegaly are the somatostatin receptor ligands due to their effectiveness in controlling gh excess in 60-70 % of patients and their beneficial effects on tumor volume. |
2011-05-27 |
2023-08-12 |
Not clear |
| Orsolya Nemes, Emese Mezos. [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review]. Orvosi hetilap. vol 152. issue 18. 2011-05-27. PMID:21498160. |
the authors of this paper review the current medical therapy of acromegaly, focusing on the role of somatostatin receptor ligands. |
2011-05-27 |
2023-08-12 |
Not clear |
| F Bogazzi, M Lombardi, D Russo, C Sardella, F Raggi, S Brogioni, F Cetani, C Ceccarelli, G Mariani, F Basolo, E Martin. Somatostatin analogues do not affect calcium metabolism in patients with acromegaly and primary hyperparathyroidism [corrected] due to MEN 1-like syndrome. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 43. issue 2. 2011-05-24. PMID:20972944. |
somatostatin analogues do not affect calcium metabolism in patients with acromegaly and primary hyperparathyroidism [corrected] due to men 1-like syndrome. |
2011-05-24 |
2023-08-12 |
Not clear |
| Aart-Jan van der Lely, Ignacio Bernabeu, Jan Cap, Philippe Caron, Annamaria Colao, Josef Marek, Sebastian Neggers, Pascal Birma. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. European journal of endocrinology. vol 164. issue 3. 2011-04-18. PMID:21148630. |
coadministration of lanreotide autogel and pegvisomant normalizes igf1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. |
2011-04-18 |
2023-08-12 |
Not clear |
| Gherardo Mazziotti, Teresa Porcelli, Fausto Bogazzi, Giovanna Bugari, Salvatore Cannavò, Annamaria Colao, Renato Cozzi, Laura De Marinis, Ettore degli Uberti, Silvia Grottoli, Francesco Minuto, Marcella Montini, Maurizio Spinello, Andrea Giustin. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. European journal of endocrinology. vol 164. issue 3. 2011-04-18. PMID:21212103. |
effects of high-dose octreotide lar on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. |
2011-04-18 |
2023-08-12 |
Not clear |
| M C De Martino, R S Auriemma, G Brevetti, G Vitale, V Schiano, M Galdiero, L Grasso, G Lombardi, A Colao, R Pivonell. The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. Journal of endocrinological investigation. vol 33. issue 9. 2011-03-14. PMID:20595800. |
the treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. |
2011-03-14 |
2023-08-12 |
Not clear |
| b' Pia Burman, Jan Besjakov, Tor Svensj\\xc3\\xb. Large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 20. issue 6. 2011-03-14. PMID:21071248.' |
large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly. |
2011-03-14 |
2023-08-12 |
Not clear |
| b' Pia Burman, Jan Besjakov, Tor Svensj\\xc3\\xb. Large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 20. issue 6. 2011-03-14. PMID:21071248.' |
somatostatin analogues are the most commonly used drugs for treatment of acromegaly. |
2011-03-14 |
2023-08-12 |
Not clear |
| H-B Fiebrich, G Van Den Berg, I P Kema, T P Links, J H Kleibeuker, A P Van Beek, A M E Walenkamp, W J Sluiter, E G E De Vrie. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Alimentary pharmacology & therapeutics. vol 32. issue 11-12. 2011-02-24. PMID:21050243. |
somatostatin analogues are administered to control hormone hypersecretion in acromegaly and carcinoid patients. |
2011-02-24 |
2023-08-12 |
Not clear |
| Sebastian J Neggers, John J Kopchick, Jens O L Jørgensen, Aart J van der Lel. Hypothesis: Extra-hepatic acromegaly: a new paradigm? European journal of endocrinology. vol 164. issue 1. 2011-01-10. PMID:21045065. |
medical treatment of acromegaly with long-acting somatostatin analogs (la-smsa) and the gh receptor antagonist, pegvisomant (pegv), has made it possible to achieve normal serum igf1 concentrations in a majority of patients with acromegaly. |
2011-01-10 |
2023-08-12 |
Not clear |
| Sunil Manjila, Osmond C Wu, Fahd R Khan, Mehreen M Khan, Baha M Arafah, Warren R Selma. Pharmacological management of acromegaly: a current perspective. Neurosurgical focus. vol 29. issue 4. 2010-12-21. PMID:20887124. |
three broad drug classes are available for the treatment of acromegaly: somatostatin analogs, dopamine agonists, and gh receptor antagonists. |
2010-12-21 |
2023-08-12 |
Not clear |
| Sunil Manjila, Osmond C Wu, Fahd R Khan, Mehreen M Khan, Baha M Arafah, Warren R Selma. Pharmacological management of acromegaly: a current perspective. Neurosurgical focus. vol 29. issue 4. 2010-12-21. PMID:20887124. |
somatostatin analogs are considered as the first-line pharmacological treatment of acromegaly, although efficacy varies among the different formulations. |
2010-12-21 |
2023-08-12 |
Not clear |
| Sunil Manjila, Osmond C Wu, Fahd R Khan, Mehreen M Khan, Baha M Arafah, Warren R Selma. Pharmacological management of acromegaly: a current perspective. Neurosurgical focus. vol 29. issue 4. 2010-12-21. PMID:20887124. |
the novel multireceptor somatostatin analog pasireotide, currently in phase ii clinical trials, also shows promise in the treatment of acromegaly. |
2010-12-21 |
2023-08-12 |
Not clear |
| Sunil Manjila, Osmond C Wu, Fahd R Khan, Mehreen M Khan, Baha M Arafah, Warren R Selma. Pharmacological management of acromegaly: a current perspective. Neurosurgical focus. vol 29. issue 4. 2010-12-21. PMID:20887124. |
dopamine agonists have been the earliest and most widely used agents in the treatment of acromegaly but have been found to be less effective than somatostatin analogs. |
2010-12-21 |
2023-08-12 |
Not clear |
| Manel Puig-Domingo, Eugenia Resmini, Beatriz Gomez-Anson, Joana Nicolau, Mireia Mora, Elisabet Palomera, Camelia Martí, Irene Halperin, Susan M Web. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. The Journal of clinical endocrinology and metabolism. vol 95. issue 11. 2010-12-10. PMID:20739382. |
magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. |
2010-12-10 |
2023-08-12 |
Not clear |
| Lily P H Yang, Gillian M Keatin. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. vol 70. issue 13. 2010-12-02. PMID:20731479. |
octreotide long-acting release (lar) [sandostatin lar] is a somatostatin analogue with a well established clinical profile in patients with acromegaly. |
2010-12-02 |
2023-08-12 |
Not clear |
| Kristine Z Rubeck, Michael Madsen, Caroline Marie Andreasen, Sanne Fisker, Jan Frystyk, Jens Otto L Jørgense. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. European journal of endocrinology. vol 163. issue 5. 2010-10-26. PMID:20813787. |
conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. |
2010-10-26 |
2023-08-12 |
Not clear |
| N García Basavilbaso, M Guitelman, A Nagelberg, G Stalldecker, A Carabelli, O Bruno, K Danilowitz, M Manavela, S Mallea Gil, C Ballarino, R Guelman, D Katz, S Fidalgo, R Leal, H Fideleff, M Servidio, D Bruera, F Librandi, A Chervin, M Vitale, A Bass. Experience from the Argentine Pegvisomant Observational Study: preliminary data. Frontiers of hormone research. vol 38. 2010-09-07. PMID:20616494. |
the gh receptor antagonist pegvisomant is an efficient agent to achieve biochemical control of acromegaly in those cases refractory to surgery and medical therapy with somatostatin analogs. |
2010-09-07 |
2023-08-12 |
Not clear |